文献速递乳腺癌支持与姑息治疗

药物与生活方式联合干预用于乳腺癌预防:高危女性随机II期TOLERANT试验结果

Combined pharmacologic and lifestyle intervention for breast cancer prevention: Results of the randomized phase II TOLERANT trial in high-risk women.
PubMed 文献 · Eur J Cancer · 2026-10-14

TOLERANT试验在高危女性中比较他莫昔芬低剂量隔日(LDT)、间歇性热量限制(ICR)与生活方式干预(LI)对循环SHBG等生物标志物的影响。

要点

  • LDT±ICR可显著改善乳腺癌风险相关生物标志物(SHBG升高、IGF-I降低)。
  • ICR在LDT或LI基础上附加代谢获益,体现互补效应。
  • LDT组生活质量有轻度但显著的恶化,需权衡获益与耐受性。

核心结论

  • LDT可有利调节乳腺癌风险相关生物标志物,ICR附加互补代谢效应,支持进一步研究联合策略。

研究设计与样本

  • 四臂随机II期生物标志物试验,纳入遗传性乳腺癌风险、10年乳腺癌风险≥5%或上皮内瘤变史的女性,随机接受LDT、LDT+ICR、LI或LI+ICR干预6个月。
  • 主要终点为干预后循环SHBG水平,主要分析为LDT+ICR vs LI+ICR。

主要发现

  • LDT±ICR显著升高SHBG(绝对变化p<0.0001)、升高IGFBP-3(p=0.004)并降低IGF-I(p<0.001)。
  • ICR组较非ICR组脂联素更高(p=0.003)。
  • 依从性>90%的受试者中,LI+ICR较LI单用与更高SHBG显著相关(p=0.045)。
  • 不良事件无组间差异;LDT组生活质量有轻度但显著的恶化。

关键数值与推荐

  • SHBG绝对变化p<0.0001,IGFBP-3 p=0.004,IGF-I p<0.001(LDT±ICR组)。
  • 脂联素ICR组 vs 非ICR组p=0.003。
  • 依从性>90%亚组中LI+ICR vs LI的SHBG比较p=0.045。

临床怎么用

  • 在高危女性中,低剂量他莫昔芬隔日方案可改善风险相关生物标志物,但需关注生活质量轻度下降。
  • 间歇性热量限制可与药物或生活方式干预联合,提供额外代谢获益,尤其在高依从性人群中。

局限性

  • SHBG并非经验证的乳腺癌风险降低替代终点。
  • II期生物标志物试验样本量有限,主要分析为特定组间比较,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer (BC) prevention strategies include lifestyle modification and preventive agents such as selective estrogen receptor modulators and aromatase inhibitors. Sex hormone-binding globulin (SHBG) is a breast cancer risk-associated biomarker; however, it is not a validated surrogate endpoint for breast cancer risk reduction. METHODS: Population: women with hereditary BC risk, a ≥ 5% 10-year BC risk, or a history of intraepithelial neoplasia were enrolled. TRIAL DESIGN: a four-arm randomized phase II biomarker trial: Tamoxifen 10 mg every other day (LDT); LDT + Intermittent Caloric Restriction (ICR); Lifestyle intervention with a step counter (LI); LI + ICR. PRIMARY ENDPOINT: Post intervention levels of circulating SHBG. Secondary endpoints: modulation of IGF system, adipokines, inflammatory markers, quality of life. Main analysis was LDT+ ICR vs LI+ICR. RESULTS: One hundred and ten participants were randomized to: LDT, LDT plus ICR, LI, or LI plus ICR, for 6 months. Mean age was 52 years and mean BMI was 25 kg/m²; 62% were unaffected carriers, and 65% were postmenopausal. LDT±ICR significantly increased SHBG and IGFBP-3 and decreased IGF-I (absolute change p < 0.0001, p = 0.004, and p < 0.001, respectively). ICR arms showed higher adiponectin than non-ICR arms (p = 0.003). Furthermore, in adherent subjects (>90%), LI plus ICR was significantly associated with higher SHBG compared with LI alone (p = 0.045). No differences in adverse events between arms; LDT demonstrated a mild, although significant, worsening in quality of life. CONCLUSIONS: LDT favorably modulates BC risk-associated biomarkers, and ICR adds a complementary metabolic effect, supporting further investigation of these combined strategies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Serrano D, Lazzeroni M, Rizzo R, et al. Combined pharmacologic and lifestyle intervention for breast cancer prevention: Results of the randomized phase II TOLERANT trial in high-risk women. Eur J Cancer. 2026. PMID: 42892237. doi:10.1016/j.ejca.2026.117784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。